Effect of Continuous Glucose Monitoring System on Glycemic Control in Non-insulin-Treated Elderly People With Type 2 Diabetes

Prior treatment

• Use of insulin or Glucagon-Like Peptide-1 （GLP-1） receptor agonists within 3 months prior to screening;
• Use of any CGM device within 3 months prior to screening;
• Planned surgery or other procedures within the next 6 months that may interfere with scheduled follow-up visits;
• Participation in any other clinical trial within 3 month prior to screening, or concurrently enrolled, or planning to participate in another trial during the study period.

Other illness

• Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area;
• Considered unsuitable for participation by the investigators, including but not limited to individuals with dementia, psychiatric disorders, extreme visual or hearing impairment that would impair ability to use real-time CGM assessed;

Lab values

• Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2;

Other

• Current or anticipated acute uses of glucocorticoids (oral, injectable, or IV), that will affect glycemic control;

• Age ≥ 60 years at the time of screening;
• Diagnosed with type 2 diabetes mellitus;
• Treated with two or more oral antidiabetic drugs with a stable medication regimen (medication classes) during the 3 months prior to entry;
• Suboptimal glycemic control, defined as HbA1c ≥ 7.5% and ≤ 10% at screening or within 30 days prior to screening visit;
• Has a smart phone compatible with CGM and BGM systems;
• Willing and able to provide written informed consent;
• At least 240 hours (10 out of 14 days) of sensor glucose data from the blinded CGM pre-randomization phase.